Drugs / BEVANTOLOL
BEVANTOLOL
also known as
SOM3355 · Bevantolol hcl · bevantolol hydrochloride · Calvan · CL 775 · NSC-132348 · Vantol
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05475483 | Aug 2022 → Jun 2024 | Huntington disease | SOM Innovation Biotech SA | Completed | Met primary |
| Phase 2 | NCT03575676 | Aug 2018 → Aug 2019 | Huntington disease | SOM Innovation Biotech SA | Completed | Met primary |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-09-15 | SOM Innovation Biotech SA | Regulatory SOM Biotech receives positive EMA COMP opinion on European Orphan Drug Designation for SOM3355 for treatment of Huntington’s Disease sombiotech.com ↗
SOM Biotech, a clinical-stage company dedicated to the discovery and development of innovative therapies for rare central nervous system disorders , today announces that the European Medicines Agency (EMA) Committee for Orphan Medical Products (COMP) has issued a positive opinion on granting Orphan Drug Designation (ODD) for SOM3355 for the treatment of Huntington’s disease (HD). |
| 2025-02-06 | SOM Innovation Biotech SA | Results SOM Biotech announces the presentation of the Phase2b study results sombiotech.com ↗
SOM Biotech presents the Phase 2b study results with SOM3355 demonstrating a unique profile with robust improvements of chorea in Huntington's Disease Patients and a safe profile with no somnolence, no akathisia and no impact on depression, suicidality or cognition. |
| 2024-06-19 | SOM Innovation Biotech SA | Results The Brazilian Journal of Implantology and Health Sciences cites SOM3355 as a promising therapy for chorea in Huntington’s disease. sombiotech.com ↗
Realizado em pacientes com HD, o estudo mostrou que o SOM3355 foi capaz de melhorar significativamente a pontuação máxima total de coreia em comparação com o placebo, com 57,1% dos pacientes alcançando a melhoria primária desejada. |
| 2018-06-22 | SOM Innovation Biotech SA | Regulatory SOM Biotech receives approval to start Huntington’s disease trial sombiotech.com ↗ |
All press releases naming this drug 11 releases
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BEVANTOLOL | ChEMBL registry synonym — accepted as the source's own label CHEMBL314010 ↗ |
| Known as | Bevantolol hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL314010 ↗ |
| Known as | bevantolol hydrochloride | “A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease.” PMID 36494329 ↗ Dec 2022 |
| Known as | Calvan | ChEMBL registry synonym — accepted as the source's own label CHEMBL314010 ↗ |
| Known as | CL 775 | ChEMBL registry synonym — accepted as the source's own label CHEMBL314010 ↗ |
| Known as | NSC-132348 | ChEMBL registry synonym — accepted as the source's own label CHEMBL314010 ↗ |
| Known as | SOM3355 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03575676 ↗ |
| Known as | Vantol | ChEMBL registry synonym — accepted as the source's own label CHEMBL314010 ↗ |
| Action | Inhibit | “a β1 -adrenoreceptor antagonist with recently identified vesicular monoamine transporter type 2 inhibitory properties” PMID 36494329 ↗ Dec 2022 |
| Modality | Small molecule | — CHEMBL314010 ↗ |
| Route | Oral | “Oral” NCT03575676 ↗ |